Tigermed Company Profile

Background

Overview

Tigermed, officially known as Hangzhou Tigermed Consulting Co., Ltd., is a leading Contract Research Organization (CRO) specializing in providing comprehensive clinical research solutions for the biopharmaceutical and medical device industries. Established in 2004 by Dr. Xiaoping Ye, the company has grown to become a prominent player in the global clinical research landscape. Tigermed is publicly listed on the Shenzhen Stock Exchange (300347.SZ) and the Hong Kong Stock Exchange (3347.HK).

Mission and Vision

Tigermed's mission is to advance human health by delivering life-changing therapies through efficient and cost-effective clinical research services. The company's vision is to become a global leader in biopharmaceutical consulting and clinical research, bridging the gap between innovative medical developments and market needs.

Primary Area of Focus

Tigermed focuses on providing end-to-end clinical development services, including preclinical studies, clinical trials, regulatory affairs, data management, and post-market research. The company serves a diverse clientele, including multinational pharmaceutical companies, biotechnology firms, and medical device manufacturers.

Industry Significance

As of 2023, Tigermed held a 12.8% market share in China's clinical service market, making it the leading Chinese CRO. Globally, it was the only Chinese CRO to rank among the top 10, with a global market share of 1.4%.

Key Strategic Focus

Core Objectives

Global Expansion: Tigermed aims to strengthen its global presence by establishing offices and partnerships across various regions, including North America, Europe, and Asia-Pacific.

Service Diversification: The company seeks to expand its service offerings to cover the entire lifecycle of clinical development, from preclinical studies to post-market research.

Technological Innovation: Tigermed is committed to integrating advanced technologies, such as artificial intelligence and big data analytics, to enhance the efficiency and accuracy of clinical trials.

Areas of Specialization

Clinical Trial Management: Overseeing the planning, execution, and monitoring of clinical trials across various phases and therapeutic areas.

Regulatory Affairs: Assisting clients with submissions to regulatory bodies, ensuring compliance with local and international standards.

Data Management and Analysis: Managing and analyzing vast amounts of clinical data to support decision-making processes.

Key Technologies Utilized

Artificial Intelligence (AI): Implementing AI-driven data analytics platforms to reduce trial data processing times and enhance decision-making.

Big Data Analytics: Utilizing big data tools to manage and analyze large datasets, improving the efficiency of clinical trials.

Primary Markets Targeted

Pharmaceutical Companies: Providing comprehensive clinical research services to support drug development.

Biotechnology Firms: Assisting in the development and commercialization of innovative biotech products.

Medical Device Manufacturers: Offering regulatory and clinical research services for medical devices, including in vitro diagnostic products.

Financials and Funding

Funding History

Initial Public Offering (IPO): In August 2012, Tigermed completed an IPO on the Shenzhen Stock Exchange, raising approximately $80 million.

Series A Financing: In July 2008, Tigermed secured Series A funding from Qiming Venture Partners, a leading venture capital firm based in Shanghai.

Recent Financial Performance

2024 Financial Highlights:

Total Revenue: RMB 6,603 million, a 10.6% year-over-year decrease.

Adjusted Net Profit: RMB 855 million, a 42.1% year-over-year decline.

New Bookings: RMB 8,423 million, a 7.3% year-over-year increase.

Clinical Trial Solutions Revenue: RMB 3,178 million, a 23.8% year-over-year decrease.

Clinical-related and Lab Services Revenue: RMB 3,425 million, a 6.5% year-over-year increase.

Pipeline Development

Tigermed's pipeline development focuses on supporting clients in the approval of innovative drugs and medical devices. In 2024, the company assisted in the approval of 28 Class I new drugs and 6 innovative medical devices in China. Since 2004, Tigermed has been involved in 60% of Class I new drug approvals in China.

Technological Platform and Innovation

Proprietary Technologies

YiYa AI Intelligent Translation Platform: A self-developed intelligent translation system powered by deep learning and neural networks, enhancing the efficiency of clinical trial documentation.

Significant Scientific Methods

Remote Intelligent Decentralized Clinical Trials (DCT): Implementing remote monitoring systems and subject eligibility discussion systems to facilitate decentralized clinical trials.

Leadership Team

Key Executives

Dr. Xiaoping Ye: Founder, Chairman, and CEO. Dr. Ye established Tigermed in 2004 and has been instrumental in its growth and global expansion.

Ms. Xiaochun Cao: Co-founder and President. Ms. Cao has played a significant role in Tigermed's strategic direction and operational excellence.

Competitor Profile

Market Insights and Dynamics

The global CRO market is highly competitive, with numerous players offering a range of services. Tigermed's primary competitors include:

WuXi AppTec Co., Ltd.: A global CRO offering a broad integrated platform that includes discovery chemistry and manufacturing services.

Pharmaron Beijing Co., Ltd.: A China-based CRO with a significant presence in laboratory and clinical development services.

IQVIA Holdings Inc.: The world's largest CRO, known for its vast historical trial data and sophisticated analytics capabilities.

Strategic Collaborations and Partnerships

Tigermed has formed strategic partnerships to enhance its global reach and service offerings:

Medical Edge: Acquired in 2024, this Japanese CRO expanded Tigermed's clinical operations in Japan.

DreamCIS: A South Korean CRO acquired in 2024, strengthening Tigermed's presence in the Asia-Pacific region.

Operational Insights

Tigermed's extensive global network, comprising over 180 offices and more than 10,000 employees across 37 countries, enables it to offer localized clinical research solutions and expand existing client relationships globally.

Strategic Opportunities and Future Directions

Tigermed is well-positioned to leverage its global presence and technological innovations to expand its market share. The company's focus on integrating advanced technologies and forming strategic partnerships aligns with industry trends towards digitalization and globalization in clinical research.